← Back to Clinical Trials
Recruiting NCT07369934

NCT07369934 Virtual Reality Based Exercise Training Versus Mulligan Mobilization on Shoulder Posture and Function in Subacromial Impingement Syndrome

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07369934
Status Recruiting
Phase
Sponsor Cairo University
Condition Subacromial Impingement Syndrome
Study Type INTERVENTIONAL
Enrollment 74 participants
Start Date 2025-12-13
Primary Completion 2026-05

Eligibility & Interventions

Sex All sexes
Min Age 30 Years
Max Age 50 Years
Study Type INTERVENTIONAL
Interventions
Virtual RealityMulligan mobilization

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 74 participants in total. It began in 2025-12-13 with a primary completion date of 2026-05.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The study will compare the effect of virtual reality based exercise training versus Mulligan mobilization in addition to exercise therapy added to both groups on shoulder posture and function in subacromial impingement syndrome.

Eligibility Criteria

Inclusion Criteria: * Patients will be referred from the orthopedic surgeon with a diagnosis of stage II SIS with the following criteria: 1. Participants ranged in age from 30-50 years old. 2. Participants are from non-athletes from the general population. 3. Unilateral shoulder pain that is localized either anteriorly or laterally to the acromion. Pain that occurs or worsens when the affected shoulder is in flexion and/or abduction. 4. Four of the following should be present in the included patients: Neer impingement test, Hawkins' test, Pain was replicated in the supraspinatus empty-can test, a painful arc of movement from 70° to 120°, and painful greater tuberosity of the humerus. 5. BMI range 18.5- 29.9 Kg/m². Exclusion Criteria: * 1\) Patients who, during the previous three months, underwent shoulder physical treatment and/or an acute pain flare. 2\) Patients who have undergone surgeries for tendon repair. 3) Malignancy, epilepsy, pregnant women, and/or systemic conditions like chronic renal or liver failure. 4\) Mini-Mental State Examination test (MMSE) (\< 24/30) to exclude cognitive impairment and/or significant vision impairment (if they couldn't read the introduction while wearing the Head Mounted Device (HMD). 5\) Corticosteroid injection during the last three months or used steroids chronically. 6\) Adhesive capsulitis, glenohumeral joint instability, Numbness or tingling of the upper limb, and/or full-thickness tear of the rotator cuff.

Contact & Investigator

Central Contact

Sara M Meselhy, Demonstrator

✉ sara.mohsen@cu.edu.eg

📞 +01222518092

Principal Investigator

Enas Fawzy Youssed, Professor Doctor

STUDY CHAIR

Cairo University

Frequently Asked Questions

Who can join the NCT07369934 clinical trial?

This trial is open to participants of all sexes, aged 30 Years or older, up to 50 Years, studying Subacromial Impingement Syndrome. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07369934 currently recruiting?

Yes, NCT07369934 is actively recruiting participants. Contact the research team at sara.mohsen@cu.edu.eg for enrollment information.

Where is the NCT07369934 trial being conducted?

This trial is being conducted at Giza, Egypt.

Who is sponsoring the NCT07369934 clinical trial?

NCT07369934 is sponsored by Cairo University. The principal investigator is Enas Fawzy Youssed, Professor Doctor at Cairo University. The trial plans to enroll 74 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology